Gene · 112399
EGLN3: egl-9 family hypoxia inducible factor 3
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. EGLN3: egl-9 family hypoxia inducible factor 3. Genes, record 112399. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/112399
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q9H6Z9 | Prolyl hydroxylase EGLN3 | 239 | 0 | Ensembl, GeneID, HGNC |
Source UniProt
Patents78
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 44809 | Q9H6Z9 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 44810 | Q9H6Z9 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 936 | Q9H6Z9 | Espacenet |
| EP 4641202 A2 | 2025-10-29 | 4447 | Q9H6Z9 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 936 | Q9H6Z9 | Espacenet |
| JP 2025032204 A | 2025-03-11 | 27699 | Q9H6Z9 | Espacenet |
| WO 2025049599 A1 | 2025-03-06 | 4 | Q9H6Z9 | Espacenet |
| KR 1020250017231 A | 2025-02-04 | 4447 | Q9H6Z9 | Espacenet |
| EP 4487869 A2 | 2025-01-08 | 149 | Q9H6Z9 | Espacenet |
| US 12188096 B2 | 2025-01-07 | 56 | Q9H6Z9 | Espacenet |
1 to 10 of 78
See all 78 patentsDrugs4
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| DAPRODUSTAT | CHEMBL3544988 | Hypoxia-inducible factor prolyl hydroxylase inhibitor | INHIBITOR | ChEMBL |
| MOLIDUSTAT | CHEMBL3646118 | Egl nine homolog 3 inhibitor | INHIBITOR | ChEMBL |
| ROXADUSTAT | CHEMBL2338329 | Hypoxia-inducible factor prolyl hydroxylase inhibitor | INHIBITOR | ChEMBL |
| VADADUSTAT | CHEMBL3646221 | Egl nine homolog 3 inhibitor | INHIBITOR | ChEMBL |
Trials113
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07565701 | VADADUSTAT | PHASE3 | ClinicalTrials.gov | |
| NCT07537816 | VADADUSTAT | PHASE4 | ClinicalTrials.gov | |
| NCT07359027 | ROXADUSTAT | PHASE4 | ClinicalTrials.gov | |
| NCT07346547 | DAPRODUSTAT | ClinicalTrials.gov | ||
| NCT07300111 | DAPRODUSTAT | PHASE3 | ClinicalTrials.gov | |
| NCT07268807 | ROXADUSTAT | ClinicalTrials.gov | ||
| NCT07136792 | ROXADUSTAT | ClinicalTrials.gov | ||
| NCT07086755 | VADADUSTAT | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT07045155 | ROXADUSTAT | PHASE4 | ClinicalTrials.gov | |
| NCT06917950 | ROXADUSTAT | PHASE1/PHASE2 | ClinicalTrials.gov |
1 to 10 of 113
See all 113 trialsNIH grants1,232
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | EGLN3 papers | Newest fiscal year |
|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 7 | 2025 |
| P50CA101942 | DF/HCC Kidney Cancer SPORE (supplement) | 6 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 5 | 2025 |
| P30CA016056 | Roswell Park Cancer Center Support Grant | 5 | 2025 |
| UL1TR001863 | Yale Clinical and Translational Science Award | 5 | 2025 |
| I01BX002182 | Metabolic Regulation of Mucosal Inflammation | 4 | 2025 |
| P30CA016087 | Cancer Center Support Grant | 4 | 2025 |
| P30CA021765 | Cancer Center Support Grant (CCSG) | 4 | 2025 |
| R01CA198279 | Shaping DNA Damage Response Networks Via Histone H2A Variants | 4 | 2025 |
| R01DK095491 | Indole dysbiosis and mucosal inflammation | 4 | 2025 |
1 to 10 of 1,232Source NIH's project files
See all 1,232 nih grantsPapers2,134
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Potential Mechanisms Linking Excessive Testosterone to PMOS: Insights from Network Toxicology and Machine Learning. | Metabolites | 2026 | 42783788 | PubTator, text mining | PubMed |
| HDCA suppresses exosomal lncRNA MSTRG171708 release to inhibit Treg-mediated immunometabolism in hepatocellular carcinoma. | Mol Biomed | 2026 | 42726156 | PubTator, text mining | PubMed |
| Oxygen-dependent subcellular redistribution of PHD3 links the hypoxic microenvironment to mitochondrial metabolic reprogramming in ccRCC. | Exp Mol Med | 2026 | 42686983 | PubTator, text mining | PubMed |
| Shikonin in Hepatocellular Carcinoma: Bridging Metabolic Disruption and Immunomodulation. | J Hepatocell Carcinoma | 2026 | 42639556 | PubTator, text mining | PubMed |
| Post-Treatment Persistent Erythrocytosis in Patients with Hodgkin Lymphoma: Molecular Mechanisms Underlying the Pathogenesis of Erythrocytosis. | Cancers (Basel) | 2026 | 42588719 | PubTator, text mining | PubMed |
| Mechanism of troxerutin-mediated regulation of EGLN3/LRPPRC in B[a]P-induced lung adenocarcinoma. | Int Immunopharmacol | 2026 | 42556279 | PubTator, text mining | PubMed |
| EPAS1 knockdown is associated with cell cycle and DNA replication programs and MYC/E2F-related signatures in hemangioma endothelial cells. | PLoS One | 2026 | 42497216 | PubTator, text mining | PubMed |
| Evolutionary convergence and niche-specific regulation of core HIF1A pathway genes synergistically drive divergent hypoxia adaptation in mammals. | BMC Ecol Evol | 2026 | 42477533 | PubTator, text mining | PubMed |
| Duodenal dysbiosis is linked to altered ferroportin related transcriptomics programs in iron deficiency anemia. | Front Nutr | 2026 | 42459794 | PubTator, text mining | PubMed |
| A mechanistic computational model of the HIF signaling pathway in endothelial cells. | iScience | 2026 | 42291256 | PubTator, text mining | PubMed |
1 to 10 of 2,134
See all 2,134 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/112399
GET https://conductscience.org/api/genes/v1/112399/patents?page=2